Senior Director of Biologics Strategy and Development, Teva Pharmaceuticals
Joel Hayflick is a veteran discovery and development scientist in the biopharmaceutical industry. Currently, he is Senior Director of Biologics Strategy and Development for Teva Pharmaceuticals and advises translational groups at several academic institutions (Stanford, UCSF, Oregon Bioscience Incubator). Joel has consulted for numerous start-up companies. Before this, he was Sr. Director, Head of External R&D Innovation at Pfizer’s Rinat Labs, where he sought state-of-the-art platform technologies and drug candidates for partnerships and M&A. Earlier, he co-founded StemPar Sciences, a cancer metabolism company serving as Vice President of Research, where he built a pipeline of 3 promising drug candidates, developed the research strategy and raised seed funding. Previously, as Sr. Oncology Early Development Team Leader at Genentech, Joel was responsible for driving 5 antibody programs from lead selection through Phase 2 proof of concept. Previously, at ICOS Corp. he led target and drug discovery teams while holding various titles including Associate Director, Science and Principal Scientist. Among his accomplishments was delivery of idelalisib, a 1st-in-class PI3K delta inhibitor that has demonstrated excellent patient responses in phase 3 clinical studies and is currently being developed by Gilead Sciences. Other approved drugs he has left his mark on include tissue plasminogen activator (Activase) and human growth hormone (hGH). He earned his BA (History) from Stanford University and PhD (Cell Biology) from Oregon Health Sciences University.